Clinical Trial Update: Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy [Phase 1]

View source ↗

Summary

Phase 1 study evaluating cabozantinib plus trifluridine/tipiracil (TAS-102) as salvage therapy in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Lonsurf (trifluridine/tipiracil)
• cabozantinib (cabozantinib)

Snippet

Sponsor: University of California, Irvine | Conditions: Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Status: COMPLETED